Roche selects two more Genmab antibodies for clinical development  

2004.12.29
Copenhagen based Genmab has announced that Roche has selected two more Genmab antibodies for clinical development

Biotech company Genmab has announced that Roche has selected two more Genmab antibodies for clinical development. The antibodies are for two different disease areas, and are developed under the collaboration between Roche and Genmab which began in May 2001. Lisa N. Drakeman, CEO of Genmab says that Roche now has chosen four Genmab antibodies in total, and that Genmab continues to be pleased with the progress of the collaboration.

 

Under the agreement with Roche, Genmab creates human antibodies for a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. If all objectives are reached, the value of the collaboration to Genmab could amount to USD 100 mn (DKK 550 mn) plus royalties. The news is reported in a stock exchange release from Genmab.

 

Genmab is headquartered in Copenhagen and has operations in Utrecht, Holland and Princeton, New Jersey. Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis.

 

Link > Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×